Opiant Pharmaceuticals

Opiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. The company was founded on June 21, 2005 and is headquartered in Santa Monica, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Opiant Pharmaceuticals is a pharmaceutical company that develops treatments for drug overdose and addictions leveraging intranasal and injectable delivery technologies. The company, formerly known as Lightlake Therapeutics, was founded in 2009, has a team of addiction experts, and is headquartered in Santa Monica, California.

SANTA MONICA, Calif., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Correction: Opiant Pharmaceuticals, Inc. (“Opiant” or “Company”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, reports that the company mistakenly reissued the press release this afternoon entitled, "Opiant Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)." This press release is a duplicate of the press release issued on December 20, 2021. The company regrets the error.

Correction: Opiant Pharmaceuticals Corrects Error in Issuing Duplicate Press Release Today

Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q3 2021 Results - Earnings Call Transcript

SANTA MONICA, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three and nine months ended September 30, 2021, and provided a corporate update. Recent highlights include:

Opiant Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Corporate Update

SANTA MONICA, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (Nasdaq: OPNT), a company advancing medicines to better treat addictions and drug overdose, today announced that members of the company's senior management team will participate in the 12th Jefferies London Healthcare Conference virtually on Thursday, November 18 and Friday, November 19. Management will participate in investor 1x1 meetings on both days. A webcast of the event will be available from November 18, 2021, 8:00 AM GMT / 3:00 AM ET on the Opiant website.

Opiant Pharmaceuticals to present at Jefferies Virtual London Healthcare Conference

SANTA MONICA, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a company advancing medicines to better treat addictions and drug overdose, today announced that the U.S. Food and Drug Administration (“FDA”) has granted fast track designation for OPNT003, nasal nalmefene, its investigational treatment for opioid overdose.

Opiant Receives FDA Fast Track Designation for OPNT003, Nasal Nalmefene, for Treatment of Opioid Overdose

SANTA MONICA, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a company advancing medicines to better treat addictions and drug overdose, today announced the publication of a manuscript entitled “ Treatment of Overdose in the Synthetic Opioid Era ” authored by Phil Skolnick, PhD, DSc (hon.), Opiant's Chief Scientific Officer. The paper is published in the peer-reviewed journal Pharmacology & Therapeutics and can be viewed at: https://www.sciencedirect.com/science/article/pii/S0163725821002217?via%3Dihub

Opiant Announces Publication of Manuscript Treatment of Overdose in the Synthetic Opioid Era in Peer-Reviewed Journal Pharmacology & Therapeutics

SANTA MONICA, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report third quarter 2021 financial results and pipeline updates on Thursday, November 11, 2021, after U.S. financial markets close.

Opiant Pharmaceuticals to Report Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 11, 2021

SANTA MONICA, Calif., Aug. 25, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (Nasdaq: OPNT) today announced that members of the company's senior management team will participate in the following virtual investor conferences:

Opiant Pharmaceuticals to Participate in September Investor Conferences

Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q2 2021 Results - Earnings Call Transcript

SANTA MONICA, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three and six months ended June 30, 2021, and provided a corporate update. Recent highlights include:

Opiant Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Corporate Update

SANTA MONICA, Calif., July 20, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced, as required by Nasdaq Stock Market rules, the grant of inducement awards to two new employees.

Opiant Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SANTA MONICA, Calif., July 12, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced the appointment of Matthew Ruth as Chief Commercial Officer. Mr. Ruth brings significant commercial experience to Opiant, including leading the highly successful launch and commercialization of the first nasal naloxone spray approved by the U.S. Food and Drug Administration (“FDA”) to treat opioid overdose. Mr. Ruth will begin his employment with Opiant effective today and report directly to Dr. Roger Crystal, President and CEO.

Opiant Pharmaceuticals Announces Appointment of Matthew Ruth as Chief Commercial Officer

Opiant Pharmaceuticals Inc (NASDAQ: OPNT) announced top-line results from its confirmatory pharmacokinetic study for OPNT003, nasal nalmefene, for opioid overdose.  The 68-subject study compared 3mg nalmefene nasal spray with 1 mg intramuscular nalmefene injection.

Opiant Pharma Stock Surges On Positive Nasal Nalmefene Data In Opioid Overdose Study

The stock price of Opiant Pharmaceuticals Inc (NASDAQ: OPNT) increased by over 40% pre-market. This is why it happened.

Opiant Pharmaceuticals Stock Price Increases Over 40% Pre-Market: Why It Happened

SANTA MONICA, Calif., July 06, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced positive top-line results from its confirmatory pharmacokinetic (“PK”) study for OPNT003, nasal nalmefene, for opioid overdose.

Opiant Pharmaceuticals Announces Positive Top-line Results of Confirmatory Pharmacokinetic (PK) Study for OPNT003, Nasal Nalmefene, a Novel Investigational Treatment for Opioid Overdose

SANTA MONICA, Calif., May 24, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, announced today that its Chief Executive Officer, Dr. Roger Crystal, will present at the Jefferies Virtual Healthcare Conference, from 3:30-3:55pm ET on Thursday, June 3, 2021. Opiant will also host 1x1 investor meetings during the conference.

Opiant Pharmaceuticals to Present at the 2021 Jefferies Virtual Healthcare Conference

SANTA MONICA, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, announced today that, due to the continuing public health concerns relating to the coronavirus (COVID-19) pandemic, and to protect the health and well-being of its shareholders, employees, and other stakeholders, Opiant's 2021 Annual Meeting of Shareholders will be held in a virtual-only meeting format via live audio webcast. The original date and time of the 2021 Annual Meeting, as well as the matters to be voted on at the 2021 Annual Meeting, remain unchanged.

Opiant Pharmaceuticals to Hold Virtual 2021 Annual Shareholder Meeting on Tuesday, June 15, 2021 at 9:00am PDT

Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q1 2021 Results - Earnings Call Transcript

Shares of Opiant Pharmaceuticals (NASDAQ:OPNT) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share fell 65.00% over the past year to ($0.66), which beat the estimate of ($0.71).

Opiant Pharmaceuticals: Q1 Earnings Insights

SANTA MONICA, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months ended March 31, 2021, and provided a corporate update. Recent highlights include:

Opiant Pharmaceuticals Announces First Quarter 2021 Financial Results and Corporate Update

SANTA MONICA, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report its financial results for the first quarter ended March 31, 2021, after the financial markets close on Tuesday, May 11, 2021.

Opiant Pharmaceuticals to Report First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 11, 2021

Opiant Pharmaceuticals Inc (NASDAQ: OPNT) has dosed the first subjects in a head-to-head clinical study comparing the effectiveness of its investigational opioid antagonist nasal nalmefene (OPNT003) with nasal naloxone. The Phase 1 study in healthy volunteers will evaluate the effectiveness of 3mg nasal nalmefene compared to 4 mg nasal naloxone to reverse the respiratory depression produced by the synthetic opioid remifentanil.

Opiant Pharma's Starts Dosing In Nasal Nalmefene Comparison Study For Remifentanil-Related Respiratory Depression

SANTA MONICA, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced that the first subjects were dosed in a head-to-head clinical study comparing the effectiveness of its investigational opioid antagonist OPNT003, nasal nalmefene, with nasal naloxone.

Opiant Pharmaceuticals Announces First Subjects Dosed in Study Comparing OPNT003, Nasal Nalmefene, With Nasal Naloxone

SANTA MONICA, Calif., March 31, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, has been awarded the third and final tranche of $1.8 million from the total grant of approximately $7.4 million from the National Institute on Drug Abuse (“NIDA”), part of the National Institutes of Health (“NIH”), to support the development of OPNT003, nasal nalmefene, for the treatment of opioid overdose. The grant was awarded under award number 5U01DA046093-03.

Opiant Pharmaceuticals Announces Final Tranche of NIDA Grant Award for its Investigational Treatment for Opioid Overdose

SANTA MONICA, Calif., March 22, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced the appointment of Lorianne Masuoka, M.D., to its Board of Directors, effective immediately. Dr. Masuoka will establish and chair a science and technology Board Committee.

News for Opiant Pharmaceuticals Stock (OPNT)